Fennec announces Pedmarqsi positive recommendation by NICE

Fennec (FENC) Pharmaceuticals announced that Norgine Pharmaceuticals, a European specialist pharmaceutical company, has received positive final draft guidance from National Institute for Health and Care Excellence recommending Pedmarqsi for the prevention of cisplatin-induced hearing loss in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors. Pedmarqsi is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity, or hearing loss, induced by cisplatin chemotherapy in patients 1 month to less than18 years of age with localized, non-metastatic solid tumors. In March, Fennec entered into an exclusive licensing agreement under which Norgine will commercialize Pedmarqsi in Europe, Australia, and New Zealand.